Urteste S.A. (URT.WA)
PLN 92.8
(-1.28%)
PLN 92.8
(-1.28%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -479 Thousand PLN | -66.32% |
| 2022 | -288 Thousand PLN | -146.98% |
| 2021 | -116.6 Thousand PLN | -123.56% |
| 2020 | 494.99 Thousand PLN | 1730.37% |
| 2019 | -30.36 Thousand PLN | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -275 Thousand PLN | -57.14% |
| 2024 Q2 | -1.04 Million PLN | 78.55% |
| 2023 Q4 | -175 Thousand PLN | -8.7% |
| 2023 Q1 | -43 Thousand PLN | 72.44% |
| 2023 Q2 | -100 Thousand PLN | -132.56% |
| 2023 Q3 | -161 Thousand PLN | -61.0% |
| 2023 FY | -775 Thousand PLN | -169.1% |
| 2022 Q1 | -85.12 Thousand PLN | -38.17% |
| 2022 FY | -288 Thousand PLN | -146.98% |
| 2022 Q4 | -156 Thousand PLN | -73.33% |
| 2022 Q3 | -90 Thousand PLN | 39.19% |
| 2022 Q2 | -148 Thousand PLN | -73.86% |
| 2021 Q4 | -61.6 Thousand PLN | -76.03% |
| 2021 Q3 | -35 Thousand PLN | -131.94% |
| 2021 Q2 | 109.58 Thousand PLN | 1109.44% |
| 2021 Q1 | -10.85 Thousand PLN | 0.0% |
| 2021 FY | -116.6 Thousand PLN | -123.56% |
| 2020 Q2 | -35.46 Thousand PLN | 0.0% |
| 2020 FY | 494.99 Thousand PLN | 1730.37% |
| 2019 FY | -30.36 Thousand PLN | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioceltix S.A. | -1.03 Million PLN | 53.857% |
| BIOTON S.A. | 72.85 Million PLN | 100.657% |
| Captor Therapeutics Spolka Akcyjna | 6.9 Million PLN | 106.941% |
| Mabion S.A. | 114.58 Million PLN | 100.418% |
| Molecure S.A. | -4.1 Million PLN | 88.322% |
| NanoGroup S.A. | -79.01 Thousand PLN | -506.199% |
| Pharmena S.A. | 5.84 Million PLN | 108.198% |
| Poltreg S.A. | -1.38 Million PLN | 65.465% |
| Pure Biologics Spólka Akcyjna | -2.57 Million PLN | 81.391% |
| Ryvu Therapeutics S.A. | 29.3 Million PLN | 101.634% |
| Synthaverse S.A. | 35.16 Million PLN | 101.362% |